All In MedTech

FDA Clearance Tracker · K232017

ARK Methotrexate II Assay

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: Dec 20, 2023 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Dec 20, 2023

Substantially Equivalent

Time to decision

166 days

Received Jul 7, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Unclassified

The decision

FDA number
K232017
Device name
ARK Methotrexate II Assay
Applicant location
Fremont, CA
Received
Jul 7, 2023
Decided
Dec 20, 2023
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Unclassified

Every decision under product code LAO

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code LAO. The earliest in FDA's data is K781381, decided Oct 10, 1978.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Ark Diagnostics, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.